Oxaliplatin Accord (Oxaliplatin)

Oxaliplatin Accord is used in the treatment of cancers that involve the colorectal pathway and related solid tumours.

• Colorectal cancer: enhances the efficacy of combination chemotherapy regimens and helps achieve tumour shrinkage.
• Gastric cancer: contributes to disease control when used with other agents.
• Pancreatic cancer: used as part of multi‑drug protocols to improve response rates.
• Ovarian cancer: added to standard regimens to increase progression‑free survival.
• Metastatic adenocarcinoma: employed in combination therapy to extend overall survival.

• Oxaliplatin exerts its antitumour activity by forming platinum‑DNA adducts that disrupt DNA replication and transcription. The resulting DNA cross‑links trigger cell‑cycle arrest and apoptosis, particularly in rapidly dividing cancer cells, while sparing most normal tissues.

Oxaliplatin Accord may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea and vomiting: mild to moderate gastrointestinal upset.
• Peripheral neuropathy: tingling or numbness, often dose‑related.
• Fatigue: generalised tiredness during treatment cycles.
• Diarrhoea: loose stools that may require supportive care.
• Thrombocytopenia: reduced platelet count increasing bleed risk.

Serious or Rare Side Effects

• Severe hypersensitivity reactions: anaphylaxis or bronchospasm.
• Acute neurotoxicity: sudden onset of muscle cramps or spasms.
• Hemolytic‑uremic syndrome: rare renal and hematologic complication.
• Cardiotoxicity: arrhythmias or myocardial injury in susceptible patients.
• Neutropenic sepsis: life‑threatening infection due to low neutrophil counts.

When using Oxaliplatin Accord, clinicians should consider several safety measures to minimise risks.

• Renal function: assess baseline creatinine and monitor during therapy.
• Neuropathy monitoring: evaluate sensory changes before each cycle.
• Hematologic surveillance: perform regular CBCs to detect cytopenias.
• Hypersensitivity risk: be prepared to manage acute allergic reactions.
• Pregnancy and lactation: avoid use unless benefits outweigh potential fetal harm.
• Store at ambient temperature: keep in original container, protect from light and moisture.

Oxaliplatin Accord can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Nephrotoxic agents: concurrent use with high‑dose cis‑cis may increase kidney injury risk.
• Anticoagulants: may potentiate bleeding when thrombocytopenia is present.
• Live vaccines: immunosuppression can reduce vaccine effectiveness.

Moderate Interactions (Monitor Closely)

• CYP450 inducers: may affect plasma levels of co‑administered drugs.
• Antacids containing magnesium or aluminum: can alter drug stability in infusion solutions.
• Radiotherapy: combined neurotoxicity risk requires dose adjustments.